Appendix

Very Low Carbohydrate Diet Enhances Human T Cell Immunity through Immunometabolic Reprogramming

Simon Hirschberger^{1,2,†}, Gabriele Strauß^{1,2,†}, David Effinger^{1,2}, Xaver Marstaller¹, Alicia Ferstl¹, Martin Bernhard Müller^{1,2}, Tingting Wu¹, Max Hübner^{1,2}, Tim Rahmel³, Hannah Mascolo¹, Nicole Exner⁴, Julia Heß^{5,6}, Friedrich Wilhelm Kreth¹, Kristian Unger^{5,6}, Simone Kreth^{1,2,*}

† These authors contributed equally.

1 Walter Brendel Center of Experimental Medicine, Ludwig-Maximilian-University München (LMU), Munich, 81377, Germany.

2 Department of Anaesthesiology and Intensive Care Medicine, Research Unit Molecular Medicine, LMU

University Hospital, Ludwig-Maximilian-University München (LMU), Munich, 81377, Germany.

3 Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University Hospital

Knappschaftskrankenhaus Bochum, Bochum, 44892, Germany.

4 Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilian-University München (LMU), Munich, 81377, Germany.

5 Helmholtz Center Munich, Research Unit Radiation Cytogenetics, Neuherberg, 85764, Germany.

6 Department of Radiation Oncology, LMU University Hospital, Ludwig-Maximilian-University München (LMU), Munich, 81377, Germany.

* Correspondence: Simone Kreth, MD, PhD. Walter Brendel Center of Experimental Medicine, Ludwig-Maximilian-University München (LMU). Marchioninistreet 68, 81377, Munich, Germany. <u>simone.kreth@med.uni-</u> <u>muenchen.de</u>. +49 - 89 - 2180 76508 Appendix

Appendix Figure S1 No T cell immunostimulatory effect of BHB.

Appendix Figure S2 No nonspecific immune stimulation through ketogenic diet in vivo.

Appendix Table 1: qRT-PCR Primer and Probes













D

I

5,0M

4,0M

2,0M 1,0M

OS 3.0M

IFN γ / reference



GZMB / reference



PRF1 / reference

TGFB1 / reference NC BHB

p=0.1048

, only

i

2mm Smm

p=0.0895

Ε 0.8

Tbet / reference





20





BHB

NC



BHB

NC



÷ ŧ

1

NC BHB

I



. ج^ن









Appendix Figure S1 No T cell immunostimulatory effect of BHB.

Human peripheral blood mononuclear cells (PBMCs) were cultivated for 48h in RPMI containing 80mg/dl glucose (NC) and supplemented with 2mM, 5mM and 10mM (Figure S1a/b/e) or only 10mM beta-hydroxybutyrate (BHB | all others). Human whole blood cells were incubated at 37°C for three hours and supplemented with 10mM BHB. A Expression of IL2, IFNy and GZMB mRNA relative to endogenous controls. T cell stimulation was performed through CD3/CD28 Dynabeads at a bead:cell ratio of 1:8. Human pan T cell RNA was isolated after 48 hours, n=5 biological replicates. B Flow cytometric quantification of intracellular IFNy and GZMB protein expression in human Pan T cells cultivated with varying concentrations of BHB as indicated. T cell stimulation as described above. Histogram plot, representative of three individual experiments from three biological replicates. C mRNA expression of CD4⁺ cytokines IL2, IL4, IL10, TGFβ1 and Foxp3 in native human T cells relative to internal controls, n=6/7/9/6/8 biological replicates. D mRNA expression of CD8⁺ cytokines IFNy, GZMB and PRF1 in native human T cells relative to internal controls. n=9/8/8 biological replicates. E Th₁/Th₂ cell transcription factors Tbet and GATA3 quantified via RT-qPCR in human Pan T cells cultivated with varying concentrations of BHB as indicated and the respective ratio of fold induction Tbet/GATA3 mRNA expression, n=6 biological replicates. F Phagocytic activity in human granulocytes and monocytes incubated with green E. coli, indicated by mean fluorescence intensity (MFI) FITC, n=6 biological replicates. G Quantification of cellular Respiratory Burst after LPS stimulation, using CellROX dye, indicated by mean fluorescence intensity (MFI) FITC in human granulocytes, n=6 biological replicates. H IL1β protein expression in the supernatant of stimulated PBMCs, n=13 biological replicates. I Representative gating strategy for flow cytometric quantification of human Treg after 5 days of Treg differentiation. Data depicted as mean ± SEM (protein data) and box plots with median, twenty-fifth and seventy-fifth percentiles and range (all other). Dots indicating individual values. *p<0.05, **p<0.01, ***p<0.001, paired t-test/ Wilcoxon matched-pairs signed rank test, as appropriate.





T'1

Appendix Figure S2 No nonspecific immune stimulation through ketogenic diet *in vivo*.

44 healthy volunteers conducted a three-week ketogenic diet (KD) with a limited carbohydrate consumption of <30g per day. Blood was taken and analyzed before starting the diet (T₀) and again after three weeks of strict adherence to the diet (T₁). PBMCs were isolated. CD4⁺/CD8⁺ T cells were separated via magnetic cell labeling. **A** IL2, IL4 and CTLA4 mRNA expression in unstimulated CD4⁺ T cells, n=20 individual human subjects. Quantification cycles for IL10 have been above the detection threshold. **B** IFN_Y, GZMB, PRF1 and CTLA4 mRNA expression in unstimulated CD8⁺ T cells, n=20 individual human subjects. **C** Ratio of fold induction Tbet/GATA3 mRNA expression in vitro (BHB/NC) and in vivo (T1/T0), n=6. Data depicted as mean with standard error mean (S2c) or box plots with median, twenty-fifth and seventy-fifth percentiles and range (all other). Dots indicating individual values. Unpaired t-test (Figure S2c), Paired t-test/Wilcoxon matched-pairs signed rank test, as appropriate.

Appendix	Table	S1:	aRT-PCR	Primer	and	Probes
Арронаіх	IUNIC	U			ana	110800

Target	Primer for	Primer rev	Probe			
ТВР	5' GAACATCATGGATCAGAACAACA 3'	5' ATAGGGATTCCGGGAGTCAT 3'	87			
SDHA	5' GAGGCAGGGTTTAATACAGCA 3'	5' CCAGTTGTCCTCCTCCATGT 3'	132			
b-Aktin	5' CCAACCGCGAGAAGATGA 3'	5' CCAGAGGCGTACAGGGATA 3'	64			
TGFB1	5' ACTACTACGCCAAGGAGGTCA 3'	5' TGCTTGAACTTGTCATAGATTTCG 3'	31			
PRF1	5' CACTCACAGGCAGCCAACT 3'	5' GGGAGTGTGTACCACATGGA 3'	26			
GZMB	5' GGGGGACCCAGAGATTAAAA 3'	5' CCATTGTTTCGTCCATAGGAG 3'	37			
IL2	5' AAGTTTTACATGCCCAAGAAG 3'	5' AAGTGAAAGTTTTTGCTTTCAGCT 3'	65			
IL4	5' TGCCTCACATTGTCACTGC 3'	5' GCACATGCTAGCAGGAAGAAC 3'	38			
IL6	5' GATGAGTACAAAAGTCCTGATCCA 3'	5' CTGCAGCCACTGGTTCTGT 3'	7			
IL7	5' TATGGGCGGTGAGAGCTT 3'	5' AGGGGAGGAAGTCCAAAGATA 3'	15			
IL7R	5' GCTTTTGAGGACCCAGATGT 3'	5' AGGCAGTTTACCTCCACGAG 3'	9			
IL10	5' TGCCTTCAGCAGAGTGAAGA 3'	5' GCAACCCAGGTAACCCTTAAA 3'	67			
IL15	5' GGAGTGAAGCTACAGACCTTCG 3'	5' TTGAAGAGCTGGCTATGG 3'	66			
IFNy	5' GGCATTTTGAAGAATTGGAAAG 3'	5' TTTGGATGCTCTGGTCATCTT 3'	21			
Foxp3	5' CCTTGCCCCACTTACAGG 3'	5' CCACCGTTGAGAGCTCCT 3'	65			
CTLA4	5' TCACAGCTGTTTCTTTGAGCA 3'	5' AGGCTGAAATTGCTTTTCACA 3'	21			
Tbet	5' TGGGTGCAGTGTGGAAAG 3'	5' TCCTGTGTTGGGGGGAGTC 3'	72			
GATA3	5' CTCATTAAGCCCAAGCGAAG 3'	5' TCTGACAGTTCGCACAGGAC 3'	71			
IL8	Roche RealTime Ready Single Assay ID 103136					